Assessment of Macrophage Activation syndromE in STill's Disease in Italy
← catalyst calendarSponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
32actual
Sites
2
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-06 | actual | When the study began enrolling |
| Primary completion | 2025-11-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-27 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Macrophage Activation Syndrome (MAS)
- Still Disease, Juvenile Onset
- Still's Disease, Adult-Onset
Primary outcomes
what the primary-completion date above is the date OFOverall survival
measured from 2012 to 2022 (data abdstraction period)
Time to laboratory value normalization
measured up to 24 weeks
Time to MAS laboratory remission
measured up to 24 weeks
Time to partial MAS laboratory remission
measured up to 24 weeks
Time to tapering of GCs
measured from index date to the last of 7 consecutive days receiving ≤1 mg/kg/day of prednisone (PDN) equivalent dose
Number of recurrent MAS episodes
measured from hospital discharge or 26-weeks from the index date, whichever occurs later, until the end of study data collection]
Administration of organ support care
measured from the index date until either the hospital discharge or 26 weeks, whichever occurs later
Characteristics of MAS treatment
measured up to 24 weeks
Clinical signs
measured at index date and 8 weeks after index date (allowed time window 6 to 12 weeks)
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed